{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Anvifen",
      "Pediatric Anxiety Rating Scale",
      "adolescents",
      "anxiety",
      "primary headaches"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "\u041e\u043f\u0440\u0435\u0434\u0435\u043b\u0438\u0442\u044c \u043a\u043e\u043c\u043e\u0440\u0431\u0438\u0434\u043d\u043e\u0441\u0442\u044c \u043f\u0435\u0440\u0432\u0438\u0447\u043d\u044b\u0445 \u0433\u043e\u043b\u043e\u0432\u043d\u044b\u0445 \u0431\u043e\u043b\u0435\u0439 (\u041f\u0413\u0411) \u0438 \u0442\u0440\u0435\u0432\u043e\u0433\u0438 \u0443 \u043f\u043e\u0434\u0440\u043e\u0441\u0442\u043a\u043e\u0432 \u0438 \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0430\u043c\u0438\u043d\u043e\u0444\u0435\u043d\u0438\u043b\u043c\u0430\u0441\u043b\u044f\u043d\u043e\u0439 \u043a\u0438\u0441\u043b\u043e\u0442\u044b (\u0410\u043d\u0432\u0438\u0444\u0435\u043d) \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0442\u0440\u0435\u0432\u043e\u0436\u043d\u043e\u0433\u043e \u0441\u0438\u043d\u0434\u0440\u043e\u043c\u0430 (750 \u043c\u0433/\u0441\u0443\u0442 \u0432 \u0442\u0435\u0447\u0435\u043d\u0438\u0435 21 \u0434\u043d\u044f).",
        "\u041d\u0430\u0431\u043b\u044e\u0434\u0430\u043b\u0438 \u0442\u0440\u0438 \u0433\u0440\u0443\u043f\u043f\u044b \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432. 1-\u044f \u0433\u0440\u0443\u043f\u043f\u0430 \u2014 84 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u0430 (15,5\u00b11,3 \u0433\u043e\u0434\u0430; 46,4% \u043c\u0430\u043b\u044c\u0447\u0438\u043a\u043e\u0432, 53,6% \u0434\u0435\u0432\u043e\u0447\u0435\u043a) \u0441 \u044d\u043f\u0438\u0437\u043e\u0434\u0438\u0447\u0435\u0441\u043a\u0438\u043c\u0438 \u041f\u0413\u0411 (\u0434\u043e 15 \u0434\u043d\u0435\u0439 \u0441 \u0413\u0411 \u0432 \u043c\u0435\u0441\u044f\u0446 \u0432 \u0442\u0435\u0447\u0435\u043d\u0438\u0435 12 \u043c\u0435\u0441); 2-\u044f \u0433\u0440\u0443\u043f\u043f\u0430 \u2014 55 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 (15,2\u00b11,4 \u0433\u043e\u0434\u0430; 44,3% \u043c\u0430\u043b\u044c\u0447\u0438\u043a\u043e\u0432, 55,7% \u0434\u0435\u0432\u043e\u0447\u0435\u043a) \u0441 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u043c\u0438 \u041f\u0413\u0411 (15 \u0434\u043d\u0435\u0439 \u0438 \u0431\u043e\u043b\u0435\u0435 \u0441 \u0413\u0411 \u0432 \u043c\u0435\u0441\u044f\u0446 \u0432 \u0442\u0435\u0447\u0435\u043d\u0438\u0435 12 \u043c\u0435\u0441); 3-\u044f \u0433\u0440\u0443\u043f\u043f\u0430 \u2014 67 \u043f\u043e\u0434\u0440\u043e\u0441\u0442\u043a\u043e\u0432 (15,7\u00b11,4 \u0433\u043e\u0434\u0430; 44,8% \u043c\u0430\u043b\u044c\u0447\u0438\u043a\u043e\u0432, 55,2% \u0434\u0435\u0432\u043e\u0447\u0435\u043a) \u0431\u0435\u0437 \u0413\u0411 (\u043d\u0435 \u0438\u0441\u043f\u044b\u0442\u044b\u0432\u0430\u043b\u0438 \u0431\u043e\u043b\u044c \u0432 \u0442\u0435\u0447\u0435\u043d\u0438\u0435 \u043f\u043e\u0441\u043b\u0435\u0434\u043d\u0438\u0445 6 \u043c\u0435\u0441). \u041f\u0440\u043e\u0432\u043e\u0434\u0438\u043b\u0430\u0441\u044c \u043e\u0446\u0435\u043d\u043a\u0430 \u0442\u0440\u0435\u0432\u043e\u0433\u0438 \u043f\u043e \u043f\u0435\u0434\u0438\u0430\u0442\u0440\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0440\u0435\u0439\u0442\u0438\u043d\u0433\u043e\u0432\u043e\u0439 \u0448\u043a\u0430\u043b\u0435 \u0442\u0440\u0435\u0432\u043e\u0433\u0438: \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u043e \u0441\u0438\u043c\u043f\u0442\u043e\u043c\u043e\u0432 (\u043f\u0430\u0446\u0438\u0435\u043d\u0442); \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u043e \u0441\u0438\u043c\u043f\u0442\u043e\u043c\u043e\u0432 (\u044d\u043a\u0441\u043f\u0435\u0440\u0442); \u0448\u043a\u0430\u043b\u0430 \u0442\u044f\u0436\u0435\u0441\u0442\u0438 (\u044d\u043a\u0441\u043f\u0435\u0440\u0442); \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u043e\u0431\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0435 (\u044d\u043a\u0441\u043f\u0435\u0440\u0442).",
        "\u0414\u043e/\u043f\u043e\u0441\u043b\u0435 \u043b\u0435\u0447\u0435\u043d\u0438\u044f: 1-\u044f \u0433\u0440\u0443\u043f\u043f\u0430 \u2014 \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u043e \u0441\u0438\u043c\u043f\u0442\u043e\u043c\u043e\u0432 (\u043f\u0430\u0446\u0438\u0435\u043d\u0442) =24 [23; 26]/9 [8; 10], \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u043e \u0441\u0438\u043c\u043f\u0442\u043e\u043c\u043e\u0432 (\u044d\u043a\u0441\u043f\u0435\u0440\u0442) =23 [22; 25]/12 [12; 13], \u0448\u043a\u0430\u043b\u0430 \u0442\u044f\u0436\u0435\u0441\u0442\u0438 (\u044d\u043a\u0441\u043f\u0435\u0440\u0442) =21 [20; 25]/9 [8; 11], \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u043e\u0431\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0435 (\u044d\u043a\u0441\u043f\u0435\u0440\u0442) =14 [13; 14]/9 [8; 9]; 2-\u044f \u0433\u0440\u0443\u043f\u043f\u0430 \u2014 \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u043e \u0441\u0438\u043c\u043f\u0442\u043e\u043c\u043e\u0432 (\u043f\u0430\u0446\u0438\u0435\u043d\u0442) =47 [46; 48]/43 [45; 47], \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u043e \u0441\u0438\u043c\u043f\u0442\u043e\u043c\u043e\u0432 (\u044d\u043a\u0441\u043f\u0435\u0440\u0442) =40 [38; 41]/39 [38; 40], \u0448\u043a\u0430\u043b\u0430 \u0442\u044f\u0436\u0435\u0441\u0442\u0438 (\u044d\u043a\u0441\u043f\u0435\u0440\u0442) =33 [31; 34]/32 [31; 34], \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u043e\u0431\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0435 (\u044d\u043a\u0441\u043f\u0435\u0440\u0442) =20 [20; 22]/19 [19; 21].",
        "\u0422\u0440\u0435\u0432\u043e\u0433\u0430 \u044f\u0432\u043b\u044f\u0435\u0442\u0441\u044f \u0447\u0430\u0441\u0442\u044b\u043c \u043a\u043e\u043c\u043e\u0440\u0431\u0438\u0434\u043d\u044b\u043c \u0441\u043e\u0441\u0442\u043e\u044f\u043d\u0438\u0435\u043c \u0443 \u043f\u043e\u0434\u0440\u043e\u0441\u0442\u043a\u043e\u0432 \u0441 \u041f\u0413\u0411, \u043e\u043d\u0430 \u0431\u043e\u043b\u0435\u0435 \u0432\u044b\u0440\u0430\u0436\u0435\u043d\u0430 \u043f\u0440\u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u041f\u0413\u0411. \u0410\u043d\u0432\u0438\u0444\u0435\u043d \u0438\u043c\u0435\u0435\u0442 \u0432\u044b\u0441\u043e\u043a\u0443\u044e \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u043f\u0440\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0442\u0440\u0435\u0432\u043e\u0433\u0438, \u043a\u043e\u043c\u043e\u0440\u0431\u0438\u0434\u043d\u043e\u0439 \u044d\u043f\u0438\u0437\u043e\u0434\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u041f\u0413\u0411, \u0443\u043c\u0435\u0440\u0435\u043d\u043d\u0443\u044e \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u043f\u0440\u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u041f\u0413\u0411. \u041b\u0435\u0447\u0435\u043d\u0438\u0435 \u0442\u0440\u0435\u0432\u043e\u0433\u0438 \u0443 \u043f\u043e\u0434\u0440\u043e\u0441\u0442\u043a\u043e\u0432 \u0441\u043b\u0435\u0434\u0443\u0435\u0442 \u043d\u0430\u0447\u0438\u043d\u0430\u0442\u044c \u043a\u0430\u043a \u043c\u043e\u0436\u043d\u043e \u0440\u0430\u043d\u044c\u0448\u0435 \u0434\u043b\u044f \u043f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0438 \u0445\u0440\u043e\u043d\u0438\u0437\u0430\u0446\u0438\u0438 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36170099",
  "DateCompleted": {
    "Year": "2022",
    "Month": "09",
    "Day": "30"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "09",
    "Day": "30"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "rus"
    ],
    "ELocationID": [
      "10.17116/jnevro202212209246"
    ],
    "Journal": {
      "ISSN": "1997-7298",
      "JournalIssue": {
        "Volume": "122",
        "Issue": "9. Vyp. 2",
        "PubDate": {
          "Year": "2022"
        }
      },
      "Title": "Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova",
      "ISOAbbreviation": "Zh Nevrol Psikhiatr Im S S Korsakova"
    },
    "ArticleTitle": "[Anxiety in children and adolescents with primary headaches: diagnosis and treatment options].",
    "Pagination": {
      "StartPage": "46",
      "EndPage": "50",
      "MedlinePgn": "46-50"
    },
    "Abstract": {
      "AbstractText": [
        "To determine the comorbidity of primary headaches (PH) and anxiety in adolescents and the effectiveness of aminophenylbutyric acid (Anvifen) in the treatment of anxiety (750 mg per day for 21 days).",
        "Group 1 - \u00abepisodic PH\u00bb (up to 15 days with headaches per month for 12 months) - 84 patients (mean age 15.5\u00b11.3 years; 46.4% boys, 53.6% girls). Group 2 - \u00abchronic PH\u00bb (15 days or more with headache per month for 12 months) - 55 patients (mean age 15.2\u00b11.4 years; 44.3% boys, 55.7% girls). Group 3 - \u00abteenagers without headache\u00bb (have not experienced pain in the last 6 months) - 67 people (mean age 15.7\u00b11.4 years; 44.8% boys, 55.2% girls). Anxiety assessment using the Pediatric Anxiety Rating Scale (PARS): number of symptoms (patient); number of symptoms (expert); severity scale (expert); clinical examination (expert).",
        "Before/after treatment: group 1 number of symptoms (patient) = 24 [23; 26]/9 [8; 10], number of symptoms (expert) = 23 [22; 25]/12 [12; 13], severity scale (expert) = 21 [20; 25]/9 [8; 11], clinical examination (expert) = 14 [13; 14]/9 [8; 9]; group 2 number of symptoms (patient) = 47 [46; 48]/43 [45; 47], number of symptoms (expert) = 40 [38; 41]/39 [38; 40], severity scale (expert) =33 [31; 34]/32 [31; 34], clinical examination (expert) = 20 [20; 22]/19 [19; 21].",
        "Anxiety is a comorbid symptom in adolescents with PH, it is more pronounced in chronic PH. Anvifen has high efficacy in the treatment of anxiety comorbid with episodic PH, moderate efficacy in chronic PH. Treatment of anxiety in adolescents should begin as early as possible to prevent chronicity of the disease."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-4244-4446"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Kazan (Volga region) Federal University, Kazan, Russia."
          },
          {
            "Identifier": [],
            "Affiliation": "Clinic of Otorhinolaryngology, Kazan, Russia."
          }
        ],
        "LastName": "Esin",
        "ForeName": "O R",
        "Initials": "OR"
      },
      {
        "Identifier": [
          "0000-0001-6762-8845"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Kazan (Volga region) Federal University, Kazan, Russia."
          },
          {
            "Identifier": [],
            "Affiliation": "Kazan Branch Campus of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia."
          }
        ],
        "LastName": "Esin",
        "ForeName": "R G",
        "Initials": "RG"
      },
      {
        "Identifier": [
          "0000-0003-0919-035X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Kazan (Volga region) Federal University, Kazan, Russia."
          }
        ],
        "LastName": "Khairullin",
        "ForeName": "I Kh",
        "Initials": "IK"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ],
    "VernacularTitle": "Trevozhnye rasstroistva u detei i podrostkov s pervichnymi golovnymi bolyami: diagnostika i vozmozhnosti terapii."
  },
  "MedlineJournalInfo": {
    "Country": "Russia (Federation)",
    "MedlineTA": "Zh Nevrol Psikhiatr Im S S Korsakova",
    "NlmUniqueID": "9712194",
    "ISSNLinking": "1997-7298"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Anxiety Disorders"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Comorbidity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Headache"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Headache Disorders"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    }
  ]
}